Patents by Inventor Charles Wei

Charles Wei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250144296
    Abstract: Methods and systems for delaying alarms that include detecting an analyte level using an analyte sensor; and delaying the annunciation of an analyte alarm after the analyte level crosses an analyte threshold, wherein the delay is based on one or both of (1) a magnitude of difference between the analyte level and the analyte threshold and (2) a duration of time in which the analyte level has crossed the analyte threshold.
    Type: Application
    Filed: January 13, 2025
    Publication date: May 8, 2025
    Applicant: ABBOTT DIABETES CARE INC.
    Inventors: Mark Sloan, Marc B. Taub, Gary A. Hayter, Wesley Scott Harper, Erwin S. Budiman, Charles Wei
  • Patent number: 12220558
    Abstract: Methods and systems for delaying alarms that include detecting an analyte level using an analyte sensor; and delaying the annunciation of an analyte alarm after the analyte level crosses an analyte threshold, wherein the delay is based on one or both of (1) a magnitude of difference between the analyte level and the analyte threshold and (2) a duration of time in which the analyte level has crossed the analyte threshold.
    Type: Grant
    Filed: January 3, 2022
    Date of Patent: February 11, 2025
    Assignee: ABBOTT DIABETES CARE INC.
    Inventors: Mark Sloan, Marc B. Taub, Charles Wei
  • Publication number: 20240358919
    Abstract: Systems comprising: an analyte sensor for providing an analyte signal representative of an analyte level; a controller in data communication with the analyte sensor and programmed to provide a recommended medication dose based on the analyte level and a medication type, the controller comprising a user interface for inputting the medication type; and a model-based safety mechanism integrated with the controller for evaluating the recommended medication dose. Wherein the model-based safety mechanism overrides the recommended medication dose and provides a safety medication dose when the model-based safety mechanism detects a risk of insulin deprivation.
    Type: Application
    Filed: July 5, 2024
    Publication date: October 31, 2024
    Inventors: Erwin S. BUDIMAN, Gary A. HAYTER, Nathan C. CROUTHER, Marc B. TAUB, Wesley Scott HARPER, Charles WEI
  • Publication number: 20230001090
    Abstract: Methods and systems for delaying alarms that include detecting an analyte level using an analyte sensor; and delaying the annunciation of an analyte alarm after the analyte level crosses an analyte threshold, wherein the delay is based on one or both of (1) a magnitude of difference between the analyte level and the analyte threshold and (2) a duration of time in which the analyte level has crossed the analyte threshold.
    Type: Application
    Filed: September 9, 2022
    Publication date: January 5, 2023
    Applicant: ABBOTT DIABETES CARE INC.
    Inventors: Mark Sloan, Marc B. Taub, Gary A. Hayter, Wesley Scott Harper, Erwin S. Budiman, Charles Wei
  • Publication number: 20220118180
    Abstract: Methods and systems for delaying alarms that include detecting an analyte level using an analyte sensor; and delaying the annunciation of an analyte alarm after the analyte level crosses an analyte threshold, wherein the delay is based on one or both of (1) a magnitude of difference between the analyte level and the analyte threshold and (2) a duration of time in which the analyte level has crossed the analyte threshold.
    Type: Application
    Filed: January 3, 2022
    Publication date: April 21, 2022
    Applicant: ABBOTT DIABETES CARE INC.
    Inventors: Mark Sloan, Marc B. Taub, Gary A. Hayter, Wesley Scott Harper, Erwin S. Budiman, Charles Wei
  • Publication number: 20220047812
    Abstract: Systems for the delivery of insulin to a patient, the system comprising: a continuous glucose sensor configured to provide a glucose level signal representative of sensed glucose; an insulin delivery device configured to deliver insulin in response to delivery control signals at a basal rate and as a bolus; and a controller programmed to receive the sensor glucose level signal and to provide a delivery control signal to an insulin delivery device to suspend a basal delivery rate during the provision of a bolus delivery and to automatically resume a preprogrammed basal delivery rate after a selected event.
    Type: Application
    Filed: October 28, 2021
    Publication date: February 17, 2022
    Applicant: Abbott Diabetes Care Inc.
    Inventors: Erwin S. Budiman, Gary A. Hayter, Nathan Crouther, Marc B. Taub, Wesley Scott Harper, Charles Wei
  • Patent number: 11213622
    Abstract: Methods and systems for delaying alarms that include detecting an analyte level using an analyte sensor; and delaying the annunciation of an analyte alarm after the analyte level crosses an analyte threshold, wherein the delay is based on one or both of (1) a magnitude of difference between the analyte level and the analyte threshold and (2) a duration of time in which the analyte level has crossed the analyte threshold.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: January 4, 2022
    Assignee: ABBOTT DIABETES CARE INC.
    Inventors: Mark Sloan, Marc B. Taub, Gary A. Hayter, Wesley Scott Harper, Erwin S. Budiman, Charles Wei
  • Patent number: 11185632
    Abstract: Systems comprising: an analyte sensor for providing an analyte signal representative of an analyte level; a controller in data communication with the analyte sensor and programmed to provide a recommended medication dose based on the analyte level and a medication type, the controller comprising a user interface for inputting the medication type; and a model-based safety mechanism integrated with the controller for evaluating the recommended medication dose. Wherein the model-based safety mechanism overrides the recommended medication dose and provides a safety medication dose when the model-based safety mechanism detects a risk of insulin deprivation.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: November 30, 2021
    Assignee: Abbott Diabetes Care, Inc.
    Inventors: Erwin S. Budiman, Gary A. Hayter, Nathan Crouther, Marc B. Taub, Wesley Scott Harper, Charles Wei
  • Publication number: 20210200787
    Abstract: Integrated glucose monitoring systems, comprising a memory configured to store data relating to at least two glucose measurements of a user, a glucose safe range, and exogenous data. Wherein the at least two glucose measurements of the user are at different time points t1 and t2; a user interface comprising a display; and a processor comprising computer-executable instructions. Wherein the computer-executable instructions determine a rate of change based on the at least two glucose measurements of the user; determine, based on the at least two glucose measurements of the user and the determined rate of change, a projected glucose level at a future time t3; and provide an alarm at the user interface if, based on at least one point of exogenous data, the projected glucose level at future time t3 is outside of the glucose safe range.
    Type: Application
    Filed: December 17, 2020
    Publication date: July 1, 2021
    Applicant: Abbott Diabetes Care Inc.
    Inventors: Charles Wei, Gary Alan Hayter
  • Patent number: 10872102
    Abstract: Continuous glucose monitoring (CGM) data and insulin delivery data are used to generate more reliable projected alarms related to a projected glucose levels. A memory stores endogenous data related to measurements of glucose level in a patient, and also stores exogenous data, such as insulin on board, both of which are used by a processor to create projected alarms. Profiles of CGM data are created for use in tuning patient-specific insulin data, such at basal rate, carb ratio, and insulin sensitivity. A processor searches for patterns in the data profiles and if found, recommended changes to patient-specific insulin data are provided to permit more accurate control over a patient's glucose levels.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: December 22, 2020
    Assignee: Abbott Diabetes Care Inc.
    Inventors: Charles Wei, Gary Alan Hayter
  • Publication number: 20200197607
    Abstract: Systems comprising: an analyte sensor for providing an analyte signal representative of an analyte level; a controller in data communication with the analyte sensor and programmed to provide a recommended medication dose based on the analyte level and a medication type, the controller comprising a user interface for inputting the medication type; and a model-based safety mechanism integrated with the controller for evaluating the recommended medication dose. Wherein the model-based safety mechanism overrides the recommended medication dose and provides a safety medication dose when the model-based safety mechanism detects a risk of insulin deprivation.
    Type: Application
    Filed: March 4, 2020
    Publication date: June 25, 2020
    Applicant: Abbott Diabetes Care Inc.
    Inventors: Erwin S. Budiman, Gary A. Hayter, Nathan Crouther, Marc B. Taub, Wesley Scott Harper, Charles Wei
  • Patent number: 10583251
    Abstract: Safety features are applied to an integrated insulin delivery system to enhance safety by controlling medication delivery including the automatic resumption of basal rate after a particular event, such as termination of a bolus, expiration of a time period, delayed resumption after the bolus has terminated, IOB comparison, and others. Other safety features include overriding a delivery control that may result in hypoglycemia, and terminating an extended bolus or temporary basal rate in view of a glucose signal indicating imminent carbohydrate deficiency. In another feature, an automatic resumption of a basal delivery rate is programmed into the delivery device to avoid the possibility of complete loss of delivery of insulin in the event that communication with the delivery device is disrupted.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: March 10, 2020
    Assignee: Abbott Diabetes Care Inc.
    Inventors: Erwin S. Budiman, Gary A. Hayter, Nathan Crouther, Marc B. Taub, Wesley Scott Harper, Charles Wei
  • Publication number: 20200016338
    Abstract: Methods and systems for delaying alarms that include detecting an analyte level using an analyte sensor; and delaying the annunciation of an analyte alarm after the analyte level crosses an analyte threshold, wherein the delay is based on one or both of (1) a magnitude of difference between the analyte level and the analyte threshold and (2) a duration of time in which the analyte level has crossed the analyte threshold.
    Type: Application
    Filed: September 4, 2019
    Publication date: January 16, 2020
    Applicant: Abbott Diabetes Care Inc.
    Inventors: Mark Sloan, Marc B. Taub, Gary A. Hayter, Wesley Scott Harper, Erwin S. Budiman, Charles Wei
  • Publication number: 20190054237
    Abstract: Safety features are applied to an integrated insulin delivery system to enhance safety by controlling medication delivery including the automatic resumption of basal rate after a particular event, such as termination of a bolus, expiration of a time period, delayed resumption after the bolus has terminated, IOB comparison, and others. Other safety features include overriding a delivery control that may result in hypoglycemia, and terminating an extended bolus or temporary basal rate in view of a glucose signal indicating imminent carbohydrate deficiency. In another feature, an automatic resumption of a basal delivery rate is programmed into the delivery device to avoid the possibility of complete loss of delivery of insulin in the event that communication with the delivery device is disrupted.
    Type: Application
    Filed: October 24, 2018
    Publication date: February 21, 2019
    Applicant: Abbott Diabetes Care Inc.
    Inventors: Erwin S. Budiman, Gary A. Hayter, Nathan Crouther, Marc B. Taub, Wesley Scott Harper, Charles Wei
  • Patent number: 10130765
    Abstract: Safety features are applied to an integrated insulin delivery system to enhance safety by controlling medication delivery including the automatic resumption of basal rate after a particular event, such as termination of a bolus, expiration of a time period, delayed resumption after the bolus has terminated, IOB comparison, and others. Other safety features include overriding a delivery control that may result in hypoglycemia, and terminating an extended bolus or temporary basal rate in view of a glucose signal indicating imminent carbohydrate deficiency. In another feature, an automatic resumption of a basal delivery rate is programmed into the delivery device to avoid the possibility of complete loss of delivery of insulin in the event that communication with the delivery device is disrupted.
    Type: Grant
    Filed: November 11, 2013
    Date of Patent: November 20, 2018
    Assignee: Abbott Diabetes Care Inc.
    Inventors: Erwin S. Budiman, Gary A. Hayter, Nathan Crouther, Marc B. Taub, Wesley Scott Harper, Charles Wei
  • Publication number: 20180197628
    Abstract: Systems, devices, and methods for detecting, measuring and classifying meals for an individual based on analyte measurements are described. These results and related information can be presented to the individual to show the individual which meals are causing the most severe analyte response. These results can be organized and categorized based on preselected criteria or previous meals and results so as to organize and present the results in a format with reference to glucose as the monitored analyte. Systems, devices, and methods for determining a medication dose based on experiential data and for menu planning are also described.
    Type: Application
    Filed: January 5, 2018
    Publication date: July 12, 2018
    Inventors: Charles Wei, Nathan Crouther, Roy Tsuchida, Gary A. Hayter
  • Publication number: 20170035969
    Abstract: Various systems and methods for improving the usability of continuous glucose monitors and drug delivery pumps are described.
    Type: Application
    Filed: September 30, 2016
    Publication date: February 9, 2017
    Inventors: Mark Sloan, Marc B. Taub, Gary A. Hayter, Wesley Scott Harper, Erwin S. Budiman, Charles Wei
  • Publication number: 20160331287
    Abstract: Analyte monitoring devices, systems, and methods are provided that relate to: enabling different application features on a data processing device for analyte monitoring devices with different analyte monitoring features; programming analyte monitoring devices in advance; personalizing an analyte monitoring device; graphically representing a remaining insulin level in a user body; and graphically representing analyte measurement related data for on-demand readings; protecting access to feature of an analyte monitoring device.
    Type: Application
    Filed: May 16, 2016
    Publication date: November 17, 2016
    Inventors: Jonathan Fern, Mark P. Jesser, Lynn Dixon, Jai Karan, Charles Wei, Matthew T. Vogel, Timothy S. Gasperak, Kim Cullen, Kim Ladin, Marc B. Taub, Gary A. Hayter
  • Publication number: 20160203275
    Abstract: A system for generating a report having varying integrated levels of medical information related to a health condition is provided. The system comprises a host server having a host database and a client component that connects to the host server. The client component includes a report software application that is configured to generate a report and provide a GUI on the display. A processor populates the GUI based upon received and processed medical information from the host server component and arranges the medical information in predetermined, interrelated levels. A cursor is provided to allow the user to point to an area of interest in the display and a further level of information pertaining to one or more layers of medical information is viewable by a user when the cursor is pointed over an image on the display.
    Type: Application
    Filed: November 11, 2015
    Publication date: July 14, 2016
    Inventors: Drinda Benjamin, Charles Wei, Jai Karan, Gary A. Hayter
  • Patent number: 9339219
    Abstract: Analyte monitoring devices, systems, and methods are provided that relate to: enabling different application features on a data processing device for analyte monitoring devices with different analyte monitoring features; programming analyte monitoring devices in advance; personalizing an analyte monitoring device; graphically representing a remaining insulin level in a user body; and graphically representing analyte measurement related data for on-demand readings; protecting access to feature of an analyte monitoring device.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: May 17, 2016
    Assignee: Abbott Diabetes Care Inc.
    Inventors: Jonathan Fern, Mark P. Jesser, Lynn Dixon, Jai Karan, Charles Wei, Matthew T. Vogel, Timothy S. Gasperak, Kim Cullen, Kim Ladin, Marc B. Taub, Gary A. Hayter